In this scenario, only VISTA 1 and CD3+lymphocytes, indicating that VISTA 1 integrated with the classic TNM stage and density of CD3 lymphocytes can select patient at advanced stage as candidate for VISTA as another compensatory inhibitory pathway in NSCLC after classical immunotherapy. Here, VSIR is linked to non-small cell lung carcinoma.